Wednesday, July 8, 2026

pharma · Hematologic Malignancies · Solid Tumor, Adult

Farmatek

Farmatek clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Aydınlı - KOSB Mah. Tuzla Kimya Sanayicileri Org. San. Böl. Analitik Cad. No:90 Tuzla, Istanbul, TR, JP HQ
1994 Founded
14 Employees
PMDA registrant Type
Company details
Status
Public
HQ
Aydınlı - KOSB Mah. Tuzla Kimya Sanayicileri Org. San. Böl. Analitik Cad. No:90 Tuzla, Istanbul, TR, JP
Founded
1994
Employees
14
Programs
26
Drugs
14
Patents
53
Intelligence · Clinical Programs

Farmatek projects

4 ClinicalTrials.gov programs sponsored by Farmatek.

Farmatek has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. FT819

    Zafatek

    Lupus Nephritis

    phase 2 mab active

    1 trial
  2. MINOCIN 100 mg capsule rigide

    Zafatek

    Depression

    phase 2 small molecule active

    1 trial
  3. ProHema-CB

    Zafatek

    Hematologic Malignancies

    phase 2 mab terminated

    1 trial
  4. ProTmune

    Zafatek

    Hematologic Malignancies

    phase 2 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Farmatek have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.